Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Itch relief showdown: which drug stops water-induced agony?

NCT ID NCT03808805

Symptom relief Sponsor: University Hospital, Brest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested two oral medications, aprepitant and hydroxyzine, to see which better reduces severe itching triggered by water contact in people with myeloproliferative neoplasms (a type of blood cancer). 63 participants who had persistent itching rated 5 or higher on a 10-point scale were randomly assigned to one of the drugs. The goal was to lower itching to 3 or below on the same scale.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

63 people

The number who actually took part.

Started

Apr 2019

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Major patients with myeloproliferative neoplasms (polycythemia vera, essential thrombocythaemia or myelofibrosis) * and treated with hydroxyurea, pipobroman, anagrelide, α2a pegylated interferon, ruxolitinib or bled for more than 6 months * and suffering of persistent aquagenic pruritus * and with a pruritus intensity on Analogic Visual Scale \>5/10 * patients who gave their written consent for participation in the study Exclusion Criteria: * patients with a physical or psychological disability to sign the consent form * patients with myeloproliferative neoplasms and suffering of aquagenic pruritus but only treated by aspirin * patients already included in another therapeutic protocol * patients with diffuse dermatological disease where pruritus may be present (psoriasis, atopic dermatitis, prurigo * patients already on anti-anxiety and / or anti-depressant treatment * patients with absolute contraindications to the use of Aprepitant or Hydroxyzine * hypersensitivity to Aprepitant and / or Hydroxyzine or to any of their excipients * lactose intolerance * pregnant or lactating women

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aquagenic pruritus are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

acquired polycythemia vera aquagenic pruritus essential thrombocythemia myelofibrosis Myeloproliferative Disorders myeloproliferative neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aquagenic pruritus Myeloproliferative disorder

Contacts and locations

Locations

  • CHRU de Brest - Hôpital Morvan

    Brest, Brest Cedex, 29609, France

  • CHU Grenoble Alpes

    Grenoble, 38043, France

  • CHU d'Angers

    Angers, 49933, France

  • CHU de Caen

    Caen, 14033, France

  • CHU de Nantes

    Nantes, 44093, France

  • Centre Hospitalier de Cornouaille

    Quimper, Quimper, 29107, France

  • Centre Hospitalier de Douarnenez

    Douarnenez, 29171, France

  • Centre Hospitalier des Pays de Morlaix

    Morlaix, 29672, France

  • Centre Léon Bérard

    Lyon, 69373, France

  • Hôpital Pontchaillou

    Rennes, France

  • Hôpital Yves Le Foll

    Saint-Brieuc, 22027, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.